Citi raised the firm’s price target on Establishment Labs (ESTA) to $47 from $38 and keeps a Neutral rating on the shares. The firm adjusted targets in medical technology as part of a Q2 earnings preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESTA:
- Establishment Labs Holdings: Strong Buy Rating Driven by Motiva Implants’ Growing Demand and Innovation
- Strong Buy Recommendation for Establishment Labs Holdings Driven by US Launch Momentum and Promising Pipeline
- Promising Outlook for Establishment Labs: Buy Rating Affirmed Amid Strong Market Potential and Financial Guidance
- Establishment Labs Holdings: Strong Growth Potential and Strategic Initiatives Drive Buy Rating
- Establishment Labs Launches Motiva Implants in U.S.